Skip to main content
Clinical Trials/NCT06971315
NCT06971315Not yet recruitingPhase 1

Impact of Vitamin C on Pain Detection and Tolerance Threshold: a Double-blind Randomized Controlled Trial

Hopital du Sacre-Coeur de Montreal1 site in 1 country38 target enrollmentStarted: June 2, 2025Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Phase 1
Status
Not yet recruiting
Enrollment
38
Locations
1
Primary Endpoint
Pressure pain detection threshold (PPDT)

Study Overview

Brief Summary

Non-opioid treatments are increasingly sought after for managing acute pain. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) (e.g., Advil, Motrin, Naproxen) combined with acetaminophen (e.g., Tylenol) have become an alternative for relieving acute pain. However, many patients cannot tolerate or have contraindications to NSAIDs and acetaminophen.

There is therefore an urgent need for studies evaluating the analgesic effects of vitamin C in the context of acute pain. Our study is conducted with healthy volunteer participants receiving either vitamin C or a placebo to assess the analgesic effect of vitamin C by comparing pain detection and tolerance thresholds.

Detailed Description

Opioid-free treatments are increasingly sought for acute pain and NSAIDs have become an alternative to treat acute MSK pain and are often administered in addition to acetaminophen. However, NSAIDs can produce important adverse events and are contraindicated in many patients with comorbidities (e.g., heart disease, renal failure). Similarly, acetaminophen is contraindicated in patients with active liver disease or severe hepatic impairment.

Vitamin C has shown opioid sparing and anti-inflammatory effects mostly in postoperative contexts. Vitamin C has also demonstrated very low toxicity and rare contraindications at the dosage used in this study. Demonstrating that vitamin C increases pain detection and tolerance thresholds, thereby exhibiting an analgesic effect, could offer a valuable alternative or adjunct for patients who cannot tolerate or have contraindications to NSAIDs or acetaminophen, helping to reduce opioid use. With an aging population, the number of affected patients is expected to rise significantly.

The primary outcome is the pressure pain detection threshold (PPDT) measured with an algometer one to three hours after the last dose of the study drug (24 hours after the first dose of vitamin C or placebo).

Secondary outcomes are PPDT one to three hours after the first study drug dose, PPTT one to three hours after the initial dose and last dose of the study drug, and adverse events from the algometer or the vitamin C.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Basic Science
Masking
Triple (Participant, Care Provider, Investigator)

Eligibility Criteria

Ages
18 Years to 65 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •Age ≥ 18 to 65 years old;
  • •No acute or chronic pain;
  • •No pain medication;
  • •French or English-speaking

Exclusion Criteria

  • •Currently using vitamin C supplements;
  • •Pain in the last week or active cancer;
  • •Unavailable for follow-up;
  • •Allergy to milk (lactose in the placebo), or vitamin C,
  • •Treated with cyclosporine or warfarin (interaction with vitamin C);
  • •Pre-existing oxalate nephropathy, liver cirrhosis or hemochromatosis;
  • •Evidence of joint or overlying skin infection in the areas of testing.

Arms & Interventions

Placebo

Placebo Comparator

Three doses of 900 mg of placebo taken orally every 12 hours for 24 hours (baseline, 12 hours and 24 hours)

Intervention: Placebo (Other)

Vitamin C

Experimental

Three doses of 900 mg of vitamin C taken orally every 12 hours for 24 hours (baseline, 12 hours and 24 hours)

Intervention: Vitamin C (Dietary Supplement)

Outcomes

Primary Outcomes

Pressure pain detection threshold (PPDT)

Time Frame: 24 hours

Pressure pain detection threshold (PPDT) measured with an algometer one to three hours after the last dose of the study drug (24 hours after the first dose of vitamin C or placebo).

Secondary Outcomes

  • Pressure pain detection threshold one to three hours after the first study drug dose(1 hours)
  • Pressure pain tolerance threshold (PPTT) one to three hours after the last dose of the study drug(24 hours)
  • Pressure pain tolerance threshold (PPTT) one to three hours after the first dose of the study drug(1 hour)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Raoul Daoust

Dr Emergency Medicine, Professor, Clinician Researcher

Hopital du Sacre-Coeur de Montreal

Study Sites (1)

Loading locations...

Similar Trials